Exploring the therapeutic benefit of AVA-NP-695 (ENPP1 inhibitor) and DNA damage inhibition to activation of the immune system in metastatic osteosarcoma

AVA-NP-695 - Avammune

Lynparza (olaparib) - Merck (MSD), AstraZeneca

https://dx.doi.org/10.1136/jitc-2024-SITC2024.0809

Borja Ruiz Fernandez de Cordoba1; Avijit Goswami2; Sandeep Goyal3; Kawaljit Singh4; Princy Khurana4; Aditya Kulkarni4; Alejandro Sweet-Cordero1

Oct 4, 2024